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Abstract 
Aims. Ecstasy, the street name for 3,4-meththylenedioxymethamphetamine, has been 
associated with a range of psychiatric symptoms and impaired psychological health in both 
problem and recreational users. The purpose of the present paper is to determine how these 
impairments are related to the history of polydrug use, and the conditions under which 
individuals ingest ecstasy. 
Design. Associations between the variables of interest were investigated utilising 
negative binomial regression. 
Setting. Liverpool and Preston in the North West of England. 
Participants. A convenience sample of 159 recreational ecstasy/polydrug users, (80 
males, 79 females). The sample was composed primarily of undergraduates. 
 Main Outcome Measures. The dependent variable was the number of reported 
ecstasy-related adverse effects. Independent variables included quantitative aspects of ecstasy 
and other drug use, and the various beliefs and behaviours associated with ecstasy use. 
Results. The number of adverse effects was positively associated with lifetime 
exposure to ecstasy and negatively associated with period of abstinence from the drug. 
Adverse effects were more common among those who consumed ecstasy and alcohol 
concurrently, but were unrelated to other aspects of polydrug use. They were unaffected by 
whether the user took precautions when using the drug, and only weakly related to prior 
beliefs concerning the effects of ecstasy. 
Conclusions. Greater lifetime exposure to ecstasy and consuming the drug 
concurrently with alcohol, increase the likelihood of experiencing adverse effects including 
paranoia, poor general health, irritability, confusion, and moodiness. Adverse effects decrease 
with the period of abstinence from the drug.
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Evidence suggests that ecstasy use may adversely affect aspects of mood giving rise 
to heightened irritability, anxiety, and depression among currently abstinent users (e.g., 
Parrott and co-workers
[1]
). It is possible that different patterns of drug taking may be 
associated with different levels of risk. For example failing to take precautions when using 
ecstasy, such as monitoring fluid intake and keeping cool, may heighten the risks associated 
with the drug
[2]
. Alternatively the number of tablets typically taken on each occasion of use 
may determine the neurotoxic potential and the likelihood of experiencing adverse effects
[3]
. 
Since not all ecstasy users suffer adverse effects, the present paper will seek to determine 
which aspects of drug use might constitute a risk factor.  
Ecstasy-related adverse effects, including depression, ill temper, mood impairment, 
anxiety, obsessive-compulsive and anti-social tendencies, have been observed in a number of 
studies
[4-8]
. These deficits were apparent relative to non users of illicit drugs and cannabis 
only users,
[8] 
and have been observed to persist over time
[9]
.  More subtle affective reactions 
have also been observed, for example, Curran et al.
[10]
 and Hoshi et al.
[11]
 found that ecstasy 
users were more likely to attribute aggressive meanings to ambiguous sentences, compared to 
nonusers. It is also noteworthy that such individuals have directly attributed their problems to 
ecstasy use and furthermore the likelihood of them reporting symptoms has been found to be 
dose-related
[1]
.  
It must be acknowledged that some researchers have failed to find evidence of 
increased psychopathology among ecstasy users or have attributed it to other factors
[3, 12-15]
.  
Even in those studies where adverse psychiatric and affective symptoms among 
ecstasy/polydrug users have been reported (e.g., Parrott et al.
[1]
), it remains unclear whether 
these are directly related to ecstasy use or whether they reflect some pre-existing condition, 
or a combination of both of these factors. For example, ecstasy is known to cause sleep 
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problems
[16]
 and so the prior experience of sleep disturbance may in its own right affect the 
way in which ecstasy users respond. Thus it is important to investigate whether individuals 
who are experiencing negative affect do actually attribute this to their ecstasy use. On a more 
positive note, it may be that those who take precautions when using ecstasy and those who 
avoid bingeing on the drug (taking large numbers of tablets in a single session) are less likely 
to experience adverse effects. In view of the potential for harm to psychological health and 
the widespread prevalence of ecstasy use, it would be desirable to ask currently abstinent 
users to indicate directly how ecstasy in particular has affected their mood, social functioning 
and well being, and which aspects of their drug-using behaviour may have contributed to this.  
Such a study was conducted recently by our laboratory.
[17]
 We found that ecstasy 
users attributed a range of adverse effects to their use of the drug including heightened 
irritability, depression, paranoia and deteriorating health. Furthermore the length of ecstasy 
use was positively correlated with the reported number of adverse effects. However our 
previous study suffered from a number of limitations. Most importantly, we failed to consider 
the effects of the concurrent use of other drugs. For example, many ecstasy users take 
cannabis during the ‘come down’ phase in the hours immediately following their ecstasy use. 
Also users commonly report taking cocaine, alcohol, and tobacco, concurrently with ecstasy. 
It is possible therefore that some of the adverse effects that have been reported might be due 
to cocktail effects. Alternatively since cannabis has been shown to have neuroprotective 
qualities under certain conditions,
[18]
 it is possible that those who take cannabis during the 
period immediately following ecstasy use might be less susceptible to self-reported adverse 
effects.  
In the present study, we recruited additional participants thereby increasing our 
sample size substantially. We also made use of a technique that we overlooked in our 
previous investigation, i.e., negative binomial regression which is suited for count data with a 
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skewed distribution and a substantial number of zero scores. The utilisation of regression 
techniques allows us to consider how the number of reported adverse effects is related to a 
range of potential independent variables where the effects of the other variables are held 
constant. It is predicted that the number of adverse effects attributed to ecstasy use will be 
affected by, or associated with: 
1. the duration of ecstasy use, the period of abstinence, the current frequency of use and 
the total number of pills consumed since first use; 
2. whether ecstasy is consumed jointly with other drugs; 
3. whether users are aware of the view that ecstasy causes long term health problems; 
4. whether users are concerned about their ecstasy use and take precautions when 
ingesting the drug; 
5. whether users limit the number of tablets taken in a single session; 
6. the extent to which users experience sleep disturbance and health problems; 
7. the levels of underlying anxiety and depression experienced by the user. 
 
Method 
Participants 
This study makes use of an existing database that was constructed over the period 
2002 to 2010. The database includes 159 ecstasy/polydrug users (80 males, 79 females; mean 
age 21.55, S.D. 2.47), individuals who currently use or who have previously used ecstasy. On 
average, participants had 15.49 (S.D. 2.56) years of full time education. Intelligence was 
assessed through Raven’s Progressive Matrices[19] yielding an average score of 45.10 (S.D. 
8.18) out of a maximum of 60. This did not differ significantly from the mean score of 46.42 
(S.D. 7.01) from our sample of drug naive and non ecstasy users, F(1,345)=2.65, p=.105.  
The participants whose data are included in our database were recruited via direct approach to 
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university students, and by the snowball technique. Participants were requested to refrain 
from ecstasy use for at least 7 days prior to testing and were also requested not to use any 
other illicit drug for at least 24 hours prior to testing. 
 
Measures 
Drug Use 
Patterns of drug use and other relevant lifestyle variables were investigated via means 
of a background questionnaire (e.g. Fisk et al.
[18]
). For each drug, participants reported the 
frequency and duration of their use and the last occasion of use. Participants were also 
questioned concerning their past drug use which enabled us to calculate an estimate of total 
lifetime use. Ecstasy users were asked ‘Are you concerned about the possible dangers of 
using ecstasy?’ responding on a five point scale from 0 = extremely concerned, to 4 = not 
concerned. They were also asked ‘How aware are you that using ecstasy may have harmful 
long term effects?’ responding on a five point scale from 0 = very aware, to 4 = not aware. 
Users also indicated the extent to which they used other drugs (alcohol, amphetamine, 
cannabis and cocaine) concurrently with ecstasy, responding on a four point scale from1 = 
never to 4 = always. Ecstasy users were also asked to respond ‘Yes’ or ‘No’ to the following 
questions: ‘Do you take any sort of precautions when using ecstasy?’, and ‘Is there a 
maximum number of ecstasy tablets you will take in one session?’. 
Using a measure developed by Murphy et al.
[20]
 and Craig et al.
[21]
 ecstasy users were 
asked if they believed that since using ecstasy they had changed in any way. They responded 
to each of the following words: caring (-), paranoid (+), alert (-), depressed (+), sociable (-), 
aggressive (+), happy (-), healthy (-), moody (+), patient (-), irritable (+), confident (-), sad 
(+), loving(-), and confused (+), using a five point scale: much more 5, more 4, no change 3, 
less 2, and much less 1. The number of words eliciting adverse reactions was calculated. 
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Responses of 4 or 5 to words suffixed with (+) constitute an adverse reaction as do responses 
of 1 or 2 to words suffixed with (-).  
Epworth Sleepiness Scale (ESS)
 [22]
. 
The ESS represents the likelihood of dozing off during the day in various situations 
(e.g. while watching TV). Participants are asked to rate eight such situations on a scale of 0 
(would never doze off in this situation) to 3 (high chance of dozing off in this situation). The 
total score over all eight items is computed yielding possible minimum and maximum scores 
of 0 and 24 respectively. Higher scores are indicative of increased subjective daytime 
sleepiness
[22] 
with scores exceeding 9 potentially indicative of a clinically significant sleep 
disorder
[23]
. 
Mood adjective checklist. 
Anxiety and depression were measured by means of a mood adjective checklist.
[24]
 
Six words mapped onto each of these constructs (six words measuring arousal were not used 
in the present study). For each word participants rated themselves as either: not at all, 
slightly, moderately, very or extremely. The anxiety items were: tense, calm*, contented*, 
uneasy, worried, relaxed*; those covering depression were: enthusiastic*, sad, gloomy, 
depressed, happy*, cheerful*. Asterisked items were reverse scored. Maximum and minimum 
scores on the measures range from 6 to 30 with a midpoint of 18, and a total score for each 
measure was calculated by summing the responses. High scores are indicative of higher 
levels of perceived anxiety and depression.  
Results 
As is common in research of this nature most participants were polydrug users for 
whom ecstasy was their drug of choice. The extent of polydrug use is apparent in the trends 
reported in Table 1. The focus of the present study is the number of adverse effects reported 
by users. Responses for each of the specific effects are reported in Table 2. The items listed 
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in boldface type are those for which the number of negative responses exceeded the number 
of positive ones. For each participant, the number of items for which a negative response was 
made was summed and this provided the dependent variable. Thus a larger value corresponds 
to a greater number of perceived adverse effects. 
Table 3 contains the descriptives for the variables of interest. Mean anxiety levels 
were 13.07 (S.D. 3.82), which is below the midpoint of the range and not significantly 
different from the mean of 12.53 (S.D. 2.90) for our sample of drug naive and non ecstasy 
users, F(1,348)=2.26, p=.134. The equivalent figures for the depression measure were 13.36 
(S.D. 3.37) and 12.71 (S.D. 2.89) for ecstasy users and non users respectively, F(1,347)=3.80, 
p=.052.  With regard to the Epworth daytime sleepiness measure, the mean value for ecstasy 
users was 6.88 (S.D. 3.66), however, 23% of users produced values exceeding 9 which is 
potentially indicative of a clinically significant sleep disorder.  
Negative binomial regression with log link was conducted with the number of 
reported adverse effects as the dependent variable and the remaining variables listed in Table 
3 entered into the model as covariates. Three separate analyses were conducted, the results of 
which are reported in Table 4. First, all predictors were entered into the model (see the left 
hand panel of Table 4). Overall the chi-squared value indicates that the full model was 
significantly better than the constant-only model. The extent to which alcohol was consumed 
at the same time as ecstasy was statistically significant as a predictor, with a greater incidence 
of this behaviour associated with the experience of more adverse effects. None of the other 
variables reflecting joint use of ecstasy and respectively amphetamine, cannabis and cocaine, 
significantly affected the number of reported adverse effects. In relation to aspects of ecstasy 
consumption, adverse effects significantly increased with total use of the drug but declined as 
the period of abstinence from the drug lengthened. Neither the current frequency of use nor 
the time elapsed since commencing ecstasy use were statistically significant as predictors. 
9 
 
Perhaps not surprisingly, those who were not overly concerned about their use of ecstasy 
reported significantly fewer adverse effects. Other significant outcomes were related to the 
Epworth measure of daytime sleepiness: those who experienced more tiredness were also 
likely to report more adverse effects. Equally those who felt healthier reported fewer adverse 
effects, while increased anxiety was positively associated with the measure. 
Despite the apparent efficacy of the model in predicting the number of adverse 
effects, the Deviance/df parameter was greater than 1 indicating the possible presence of 
over-dispersion in the model. This remained the case after all of the non-significant predictors 
were excluded (the middle panel of Table 4). In order to deal with the problem of over-
dispersion, a scaler dispersion parameter based on the deviance statistic was applied thereby 
giving rise to a compensatory increase the standard errors for the parameter estimates.
[25,26]
 
However, with the exception of the ‘concern’ predictor all other predictors remained 
statistically significant in the model (see the right hand panel of Table 4). 
It is clear that a number of other illicit drugs were used more frequently than ecstasy 
and by implication consumed on separate occasions. In order to establish whether or not the 
propensity to report ecstasy-related adverse effects was associated with the use of these other 
drugs we introduced indicators of consumption for cannabis, cocaine, and alcohol 
respectively into the model. For cannabis and cocaine we included measures of total use, time 
since first use, period of abstinence and current frequency of use. None of these proved to be 
statistically significant as predictors. With regard to alcohol we included units consumed per 
week, time since first use and period of abstinence as predictors and again none of these 
proved to be statistically significant. The inclusion of these additional variables rendered 
health status statistically non-significant in two of the analyses. Weeks since last use of 
ecstasy was rendered non significant in the model containing aspects of cocaine use. Of the 
other predictors, concurrent alcohol use, total use of ecstasy and the anxiety measure were 
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statistically significant in all models. The daytime sleepiness measure was reduced to just 
below significance in the model containing aspects of cannabis use. 
 
Discussion 
The most commonly reported adverse effects were paranoia, impaired general health 
and moodiness with between 35 and 43% of the sample reporting these outcomes. Between 
20 and 30% of the sample reported other specific adverse effects including reduced alertness, 
heightened aggression, depression, impatience, irritability, sadness and confusion. However, 
it is noteworthy that in almost all cases the most prevalent response was ‘no change’ 
indicating that the majority of ecstasy users did not associate specific adverse outcomes with 
their use of the drug. The implication of this is that where adverse effects are experienced for 
the most part they are limited in scope and most prevalent among a subset of users. Two 
aspects of ecstasy use proved to be associated with the number of reported adverse effects. 
Firstly, greater lifetime exposure to ecstasy was associated with an increased propensity to 
report adverse effects consistent with a dose-related effect. Secondly, the number of 
perceived adverse effects declined as the period of abstinence from the drug increased. A 
possible explanation for this is that recollection of the negative aspects of drug use diminishes 
as the time since the drug was last ingested increases. Neither the length of use nor the 
current frequency of use were statistically significant as predictors in the present study. 
Surprisingly, taking precautions and limiting the number of tablets ingested in a single 
session were not significantly associated with the reported number of adverse effects. 
Previous research has demonstrated that following ingestion, ecstasy gives rise to acute and 
potentially short term post-acute affective reactions
[27]
. However the present results suggest 
that the adverse effects were not due to short term post-acute factors, since ecstasy use during 
the previous 10 days was not statistically significant as a predictor. 
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The association between lifetime exposure and reported adverse effects is consistent 
with results reported elsewhere. For example Soar et al.
[28]
 found that relative to nonusers and 
those who did not associate problems with their ecstasy use, those who viewed their use of 
the drug as problematic were impaired on a number of subscales of the Brief Symptom 
Inventory including somatisation, depression and anxiety. Consistent with the results of the 
present study, while problem users had greater lifetime exposure to ecstasy, they did not 
differ significantly in terms of length of use.  In another study the likelihood of reporting 
mood fluctuations, depression and poor sleep also increased with lifetime dose
[29]
. 
While over 25% of ecstasy users in the present study said that ecstasy had made them 
more depressed, the self-report depression measure was not significantly associated with the 
total number of adverse effects in the present study. A number of previous studies have found 
no difference in depression between ecstasy users and non users. For example, Beck 
Depression Inventory (BDI) scores did not differ between heavy ecstasy users and ecstasy 
free controls in Guillot and Greenway’s study,[30] and were only slightly elevated in heavier 
users in Falck et al’s study[15]. In other studies of ecstasy/polydrug users, lifetime and recent 
ecstasy use were found to be unrelated to self-reported depression and instead recent stressful 
life events and aspects of polydrug and tobacco use were found to be important in this 
regard
[31-34]
.  Thus while some users in the present study may believe that ecstasy has made 
them more depressed, overall the total number of adverse effects associated with the drug 
was not related to self-report depression. This is consistent with outcomes reported elsewhere 
in the literature where no direct link has been found between ecstasy use and depression. 
By way of contrast, self reported levels of anxiety in the present study were 
significantly related to the total number of reported adverse effects. Heightened anxiety 
among ecstasy/polydrug users has been reported in a number of previous studies
[8, 28,29]
. 
However, the association with ecstasy use has not always been clear cut. Instead elevated 
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anxiety levels among ecstasy users were found to be associated with the use of other licit and 
illicit drugs or with other factors such as exposure to recent stressful life events.
[31,32] 
The fact 
that in the present study there was an association between the number of adverse effects 
attributed to ecstasy and the individual’s anxiety level suggests that the two constructs share 
statistically significant unique variance. Therefore the inconsistent findings among ecstasy 
users in relation to anxiety might be due to the fact that ecstasy has anxiogenic properties 
only among a subset of users, i.e. perhaps those who experience adverse effects, and this 
subset may not be equally represented in all samples. 
 One of the major findings in the present study was that the concurrent use of alcohol 
and ecstasy was positively associated with the total number of reported adverse effects. 
Research outcomes from animal studies have demonstrated that concurrent administration of 
alcohol (ethanol) and MDMA enhances the neurotoxic potential of the latter
[35,36]
. Among 
humans, studies have revealed that ecstasy and alcohol are frequently consumed together at 
dance club venues with users often bingeing on both substances,
[37]
 and placing themselves at 
risk of serious physical harm and potentially death
[38]
. In an early study of drug-dependent 
ecstasy/polydrug users undergoing treatment, Schifano et al.
[39]
 found that the presence of 
psychopathological symptoms (e.g. depression, psychotic disorders, cognitive disturbances, 
bulimic episodes, impulse control disorders, panic disorders and social phobia) was more 
evident among those who consumed alcohol and ecstasy together. More recently, in a review 
of the literature Gouzoulis-Mayfrank and Daumann
[40]
 note that ecstasy is frequently 
consumed jointly with other drugs including alcohol and cannabis but also with stimulants 
such as amphetamine and cocaine. The present results confirm that ecstasy continues to be 
taken jointly with alcohol by a clear majority of users and that these persons are more likely 
to attribute adverse effects to the drug. To the best of our knowledge the present study is the 
first to demonstrate such an association among human recreational users. In view of the 
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enhanced neurotoxic potential demonstrated in animal studies and the acute risk of serious 
physical harm, this finding is of much potential concern.  
It is noteworthy that many of our ecstasy/polydrug users were regular users of other 
common illicit drugs including cannabis, cocaine, and amphetamine. This is not uncommon 
in samples of this kind. For example, among Scholey et al’s[41] large internet based sample, 
61%  of  moderate ecstasy users and 81% of heavy ecstasy users had also consumed cocaine. 
The equivalent figures for amphetamine were 69% and 84% and for cannabis 72% and 68%.  
Interestingly the concurrent use of ecstasy with other drugs such as cannabis, cocaine and 
amphetamine was not associated with more reported adverse ecstasy-related effects in the 
present study.   
In conclusion, ecstasy users were more likely to experience adverse effects if they had 
a larger lifetime dose and consumed the drug concurrently with alcohol. The use of other 
illicit drugs, both individually and concurrently with ecstasy, was unrelated to the prevalence 
of ecstasy-related adverse effects.  Adverse effects were positively associated with daytime 
sleepiness and anxiety, but not depression. They also declined with the period of abstinence 
from the drug. 
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Table 1. Indicators of Drug, Alcohol, and Tobacco Use 
 
 
N Mean s.d   
      
Ecstasy      
Weeks since last use 159 26.77 57.88   
Weeks since first use 159 200.25 122.55   
Total consumption (tablets) 159 511.92 952.91   
Frequency (times per week) 159 0.34 0.43   
      
Alcohol      
Weeks since last use 158 0.54 1.31   
Weeks since first use 158 399.30 149.53   
Units consumed per week
1
 159 19.13 13.22   
      
Tobacco      
Weeks since last use 108 12.34 52.84   
Weeks since first use 108 387.07 166.88   
Cigarettes consumed per day 85 9.98 6.93   
 
Amphetamine 
     
Weeks since last use 52 91.60 124.96   
Weeks since first use 52 266.23 201.82   
Total consumption (grams) 43 131.39 224.93   
Frequency (times per week) 38 0.08 0.19   
      
Cannabis      
Weeks since last use 133 22.08 56.12   
Weeks since first use 133 314.58 154.21   
Total consumption (joints) 127 3049.35 4732.44   
Frequency (times per week) 126 1.82 2.39   
      
Cocaine      
Weeks since last use 125 13.74 32.36   
Weeks since first use 127 170.50 113.52   
Total consumption (grams) 87 108.04 166.80   
Frequency (times per week) 87 0.46 0.69   
      
 
1. For example, 1 unit = 1 glass of wine; 1 measure of spirit, or half a pint of beer 
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Table 2 
Number of ecstasy users indicating changes in behaviour 
 
Ecstasy has 
made me: 
Much 
Less 
Less No 
Change 
More Much 
More 
Caring 0 8 124 23 4 
Paranoid 1 4 85 63 6 
Alert 3 32 107 13 4 
Depressed 0 6 113 37 3 
Sociable 0 6 67 69 17 
Aggressive 4 16 116 18 5 
Happy 0 11 105 37 6 
Healthy 7 61 84 7 0 
Moody 0 6 98 52 3 
Patient 2 36 113 8 0 
Irritable 0 5 110 40 4 
Confident 1 13 89 44 12 
Sad 0 8 130 21 0 
Loving 0 0 122 32 5 
Confused 1 3 110 40 5 
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Table 3 
Descriptive Statistics for the Variables in the Full Model (N=159) 
 
 
 
Mean s.d   
Adverse effects attributed to 
ecstasy (number) 
3.00 2.72   
     
Drugs used the same time as 
ecstasy
1
 
    
Alcohol 3.38 0.86   
Amphetamine 1.33 0.61   
Cannabis 2.26 1.02   
Cocaine 2.06 0.89   
     
Concerned about the effects of 
ecstasy
2
 
2.28 0.97   
Aware that  ecstasy may have 
harmful long term effects
3
 
0.82 0.76   
Ecstasy     
Weeks since last use 26.77 57.88   
Weeks since first use 200.25 122.55   
Total consumption (tablets) 511.92 952.91   
Frequency (times per week) 0.34 0.43   
Consumption during the 
previous 10 days  (tablets) 
0.80 2.28   
     
Health status
4
 3.67 0.81   
     
Epworth Sleepiness Scale 6.88 3.66   
     
Anxiety 13.07 3.82   
Depression 13.36 3.37   
     
     
 
 
1. Response scale: 1=never; 2=occasionally; 3=frequently; 4=always. 
2. Response scale: 0=extremely concerned; 1=very concerned; 2=concerned; 3=slightly 
concerned; 4=not concerned. 
3. Response scale: 0=very aware; 1=quite aware; 2=unsure; 3=not very aware; 4=not 
aware. 
4. Response scale: 1=very poor; 2=poor; 3=average; 4=good; 5=very good. 
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Table 4. Inferential Statistics for Predictors in the Full and Reduced Models  
 
 Full Model: All Predictors Reduced Model Reduced Model with Adjustment for 
Overdispersion 
 
 
B SE Wald 
Chi Sq 
(df=1) 
p    B SE Wald 
Chi Sq 
(df=1) 
p B SE Wald 
Chi Sq 
(df=1) 
p 
Drugs used the same time as ecstasy             
Alcohol .283 0.09 10.18 .001 .318 0.08 15.28 .000 .318 0.09 11.23 .001 
Amphetamine .037 0.10 0.14 .704         
Cannabis -.046 0.06 0.56 .453         
Cocaine .060 0.09 0.47 .494         
             
Concerned about the effects of ecstasy -.159 0.07 5.74 .017 -.147 0.07 5.05 .025 -.147 .08 3.71 .054 
Precautions Taken .121 0.14 0.81 .367         
Limit number of tablets per session -.159 0.13 1.43 .232         
Aware that  ecstasy may have harmful 
long term effects 
.201 0.09 5.40 .020 .133 0.08 3.06 .080 .133 0.09 2.25 .134 
             
Ecstasy             
Weeks since last use -.005 0.00 7.73 .005 -.004 0.00 6.94 .008 -.004 0.00 5.10 .024 
Weeks since first use .000 0.00 0.04 .842         
Total consumption (tablets) 1.76E-4 0.63E-4 7.88 .005 1.59E-4 0.49E-4 10.59 .001 1.59E-4 0.57E-4 7.78 .005 
Frequency (times per week) -.291 0.23 1.64 .200         
Use in the previous 10 days  -.001 0.04 0.00 .986         
             
Health status -.176 0.08 5.27 .022 -.177 0.07 5.80 .016 -.177 0.09 4.26 .039 
             
Epworth Sleepiness Scale .047 0.02 7.53 .006 .041 0.02 6.96 .008 .041 0.02 5.12 .024 
             
Anxiety .085 0.02 14.82 .000 .074 0.01 26.33 .000 .074 0.02 19.35 .000 
Depression -.020 0.03 0.58 .445         
             
Negative binomial .110    .141    .141    
Chi Sq for full model   86.74 
(df=17) 
.000   82.04 
(df=8) 
.000   60.30 
(df=8) 
.000 
Scalar for overdispersion   1.000    1.000    1.360  
Goodness of Fit (deviance/df) 1.463    1.360    1.000     
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